LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Squillace, Lino"
  2. AU="Laufs, Sebastian"
  3. AU="McCanny, Suzette"
  4. AU="McHardy, John Alexander"
  5. AU="Erdal, Ranya"
  6. AU="Li, Long-Xia"
  7. AU="Esapa, Benjamina"

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Bearing the burden of winters with COVID-19. Is the urological community ready?

    Campodonico, Fabio / Squillace, Lino / Ennas, Marco / Introini, Carlo

    Minerva urology and nephrology

    2021  Volume 74, Issue 1, Page(s) 126–127

    MeSH term(s) COVID-19/epidemiology ; Humans ; SARS-CoV-2 ; Urologic Diseases/epidemiology ; Urologic Diseases/therapy ; Urology
    Language English
    Publishing date 2021-10-29
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 3062840-4
    ISSN 2724-6442
    ISSN (online) 2724-6442
    DOI 10.23736/S2724-6051.21.04667-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective.

    Campodonico, Fabio / Ennas, Marco / Zanardi, Silvia / Zigoura, Ekaterini / Piccardo, Arnoldo / Foppiani, Luca / Schiavone, Concetta / Squillace, Lino / Benelli, Andrea / De Censi, Andrea / Grillo-Ruggieri, Filippo / Introini, Carlo

    Current cancer drug targets

    2020  Volume 21, Issue 2, Page(s) 107–116

    Abstract: The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options. To update the background knowledge of shared uro-oncologic practice, we reviewed current statements and landmarks in systemic therapy. A ... ...

    Abstract The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options. To update the background knowledge of shared uro-oncologic practice, we reviewed current statements and landmarks in systemic therapy. A number of new agents are under investigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies are under development to improve the detection rate of true non-metastatic and true metastatic patient. Five new drugs have shown to be effective on progression-free and overall survival in metastatìc prostate cancer. However, the optimal sequencing of these treatments requires further investigation. The tolerability and side effects of the new drugs are also crucial issues to be discussed, as well as their activity against the disease. The uro-oncologic team has to stay updated about new medical therapies in order to be confident in debating with other professionals involved in prostate cancer decision making. Different points of view and nuances should be shared during multidisciplinary group discussions to achieve a balanced decision in disease management.
    MeSH term(s) Androgen Antagonists/pharmacology ; Antineoplastic Agents/pharmacology ; Docetaxel/pharmacology ; Humans ; Male ; Neoadjuvant Therapy/methods ; Neoplasm Metastasis/drug therapy ; Neoplasm Staging ; Patient Care Management/methods ; Patient Care Management/trends ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology
    Chemical Substances Androgen Antagonists ; Antineoplastic Agents ; Docetaxel (15H5577CQD)
    Language English
    Publishing date 2020-10-19
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2064824-8
    ISSN 1873-5576 ; 1568-0096
    ISSN (online) 1873-5576
    ISSN 1568-0096
    DOI 10.2174/1568009620666201021163919
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top